Argent Capital Management LLC Decreases Stake in Medpace Holdings, Inc. $MEDP

Key Points

• Argent Capital Management LLC reduced its stake in Medpace Holdings, Inc. by 7.1% during the second quarter, now owning 80,247 shares worth approximately $25.2 million.
• Several other institutional investors made significant changes, with GAMMA Investing LLC increasing its stake by an astounding 41,658.9% during the first quarter.
• Medpace recently posted earnings that exceeded analysts' expectations, reporting $3.10 EPS and a revenue of $603.31 million for the last quarter, which was a 14.2% increase from the previous year.

Argent Capital Management LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 80,247 shares of the company's stock after selling 6,123 shares during the quarter. Argent Capital Management LLC owned 0.28% of Medpace worth $25,186,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in MEDP. Mawer Investment Management Ltd. acquired a new stake in shares of Medpace during the 1st quarter worth about $212,131,000. Vulcan Value Partners LLC increased its position in Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock worth $99,159,000 after buying an additional 224,578 shares during the period. Jacobs Levy Equity Management Inc. increased its position in Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock worth $37,009,000 after buying an additional 105,807 shares during the period. Invesco Ltd. increased its position in Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after buying an additional 102,015 shares during the period. Finally, GAMMA Investing LLC increased its position in Medpace by 41,658.9% during the first quarter. GAMMA Investing LLC now owns 93,540 shares of the company's stock worth $28,501,000 after buying an additional 93,316 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Activity at Medpace

In other Medpace news, Director Cornelius P. Mccarthy III sold 1,662 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director directly owned 10,197 shares in the company, valued at $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 36,196 shares of the company's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares of the company's stock, valued at $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock valued at $74,111,427 over the last three months. Insiders own 20.30% of the company's stock.

Medpace Stock Performance

MEDP opened at $498.08 on Tuesday. The business's fifty day moving average is $450.44 and its two-hundred day moving average is $356.61. The company has a market cap of $13.99 billion, a price-to-earnings ratio of 37.03, a PEG ratio of 3.14 and a beta of 1.44. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on MEDP. Barclays lifted their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Mizuho boosted their target price on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Rothschild Redb lowered Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Medpace currently has an average rating of "Reduce" and a consensus target price of $422.27.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.